-
1.发明申请公开(公告)号：US20170121780A1
公开(公告)日：2017-05-04
申请号：US15368979
申请日：2016-12-05
Applicant: GENOMIC HEALTH, INC.
Inventor： Wayne COWENS , Steven SHAK , Audrey GODDARD , Dejan KNEZEVIC , Joffre BAKER , Michael C. KIEFER , Tara MADDALA , Frederick L. BAEHNER
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , G01N33/57438 , G06N7/005 , G16B99/00 , G16H50/20
Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
-
2.发明申请公开(公告)号：US20210166790A1
公开(公告)日：2021-06-03
申请号：US16952566
申请日：2020-11-19
Applicant: Genomic Health, Inc.
Inventor： Wayne COWENS , Steven SHAK , Audrey GODDARD , Dejan KNEZEVIC , Joffre BAKER , Michael C. KIEFER , Tara MADDALA , Frederick L. BAEHNER
IPC: G16B99/00 , G06N7/00 , G01N33/574
Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
-
3.发明申请公开(公告)号：US20190095575A1
公开(公告)日：2019-03-28
申请号：US16199707
申请日：2018-11-26
Applicant: Genomic Health, Inc.
Inventor： Steven SHAK , George Andrew WATSON , Michael R. CRAGER , Tara MADDALA , Margarita LOPATIN , Audrey GODDARD , Dejan KNEZEVIC , Christer SVEDMAN
IPC: G06F19/18 , G16H50/30 , G06F19/00 , C12Q1/6886
Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
-
公开(公告)号：US20180051348A1
公开(公告)日：2018-02-22
申请号：US15674817
申请日：2017-08-11
Applicant: Genomic Health, Inc. , NSABP Foundation, Inc.
Inventor： Joffre B. BAKER , John L. BRYANT , Soonmyung PAIK , Steven SHAK
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
-
5.发明申请GENE EXPRESSION PROFILE ALGORITHM FOR CALCULATING A RECURRENCE SCORE FOR A PATIENT WITH KIDNEY CANCER 审中-公开用于计算患有KIDNY癌症的患者的复发率的基因表达简档算法公开(公告)号：US20160048632A1
公开(公告)日：2016-02-18
申请号：US14779428
申请日：2014-05-29
Applicant: GENOMIC HEALTH, INC.
Inventor： Steven SHAK , George Andrew WATSON , Michael R. CRAGER , Tara MADDALA , Margarita LOPATIN , Audrey GODDARD , Dejan KNEZEVIC , Christer SVEDMAN
CPC classification number: G06F19/18 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G06F19/00 , G06F19/70 , G16H50/30
Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
Abstract translation: 本发明提供基于算法的分子测定法，其涉及测量从肾癌患者获得的生物样品的基因的表达水平。 本发明还提供了基于从肾癌患者获得的生物样品的基因的表达水平的测量来获得患有肾癌的患者的定量评分的方法。 这些基因可以分为功能基因子集，用于计算定量评分，并且可以根据其对癌症复发的贡献来加权基因亚群。
-
Patent Agency Ranking
公开(公告)号：US20150079591A1
公开(公告)日：2015-03-19
申请号：US14490166
申请日：2014-09-18
Applicant: Genomic Health, Inc. , NSABP Foundation, Inc.
Inventor： Joffre B. BAKER , John L. BRYANT , Soonmyung PAIK , Steven SHAK
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G16B20/00 , G16B25/00
Abstract: The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.
Abstract translation: 本发明提供了可用于预测癌症患者是否可能对化疗治疗具有有益反应的基因表达信息，包括在包含从患者获得的乳腺肿瘤样品的生物样品中测量基因亚群的表达水平 获得与化疗有益反应的可能性相关的风险评分，其中所述评分包括以下变量中的至少一个：（i）复发评分，（ii）ESRI组评分; （iii）入侵小组得分; （iv）增殖组得分; 和（v）MYBL2和SCUBE2中的至少一种的RNA转录物的表达水平或相应的表达产物。 本发明还包括基于分子测定的算法来计算患者将基于风险评分对化学疗法有益的反应的可能性。
-
7.发明公开公开(公告)号：US20240096451A1
公开(公告)日：2024-03-21
申请号：US18454312
申请日：2023-08-23
Applicant: Genomic Health, Inc.
Inventor： Wayne Cowens , Steven SHAK , Audrey GODDARD , Dejan KNEZEVIC , Joffre Baker , Michael C. Kiefer , Tara MADDALA , Frederick L. Baehner
IPC: G16B99/00 , G01N33/574 , G06N7/01 , G16B25/10
CPC classification number: G16B99/00 , G01N33/57438 , G06N7/01 , G16B25/10 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
-
公开(公告)号：US20210151122A1
公开(公告)日：2021-05-20
申请号：US17086850
申请日：2020-11-02
Applicant: Genomic Health, Inc.
Inventor： Steven SHAK , George Andrew WATSON , Michael R. CRAGER , Tara MADDALA , Margarita LOPATIN , Audrey GODDARD , Dejan KNEZEVIC , Christer SVEDMAN
IPC: G16B20/00 , G16C99/00 , C12Q1/6886 , G16H50/30
Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
-
公开(公告)号：US20200255911A1
公开(公告)日：2020-08-13
申请号：US16800292
申请日：2020-02-25
Applicant: GENOMIC HEALTH, INC.
Inventor： Steven SHAK , Frederick L. BAEHNER , Tara MADDALA , Mark LEE , Robert J. PELHAM , Wayne COWENS , Diana CHERBAVAZ , Michael C. KIEFER , Michael CRAGER , Audrey GODDARD , Joffre B. BAKER
IPC: C12Q1/6886
Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
-
公开(公告)号：US20190249260A1
公开(公告)日：2019-08-15
申请号：US16282540
申请日：2019-02-22
Applicant: GENOMIC HEALTH, INC.
Inventor： Steven SHAK , Frederick L. BAEHNER , Tara MADDALA , Mark LEE , Robert J. PELHAM , Wayne COWENS , Diana CHERBAVAZ , Michael C. KIEFER , Michael CRAGER , Audrey GODDARD , Joffre B. BAKER
IPC: C12Q1/6886
CPC classification number: C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.016 seconds)
